Complement Receptor 1: Disease associations and therapeutic implications

被引：148

作者：

Khera, Rohan ^{[1
]}

Das, Nibhriti ^{[1
]}

机构：

[1] All India Inst Med Sci, Dept Biochem, New Delhi 110029, India

来源：

MOLECULAR IMMUNOLOGY | 2009年 / 46卷 / 05期

关键词：

Complement Receptor 1; Review; Therapeutic implications; Complement genetics; Disease associations; SYSTEMIC-LUPUS-ERYTHEMATOSUS; ERYTHROCYTE CR-1 EXPRESSION; KNOPS BLOOD-GROUP; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; FRAGMENT-LENGTH-POLYMORPHISM; HUMAN-IMMUNODEFICIENCY-VIRUS; DECREASED C3B RECEPTORS; HUMAN C3B/C4B RECEPTOR; IMMUNE-COMPLEXES; CD35; EXPRESSION;

D O I：

10.1016/j.molimm.2008.09.026

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

070307 [化学生物学]; 071010 [生物化学与分子生物学];

摘要：

Exaggerated complement activation is a key event in the pathogenesis of a range of autoimmune and inflammatory diseases. Complement Receptor 1 (CR1) has emerged as a molecule of immense interest in gaining insight to the susceptibility, pathophysiology, diagnosis, prognosis and therapy of such diseases. This review brings forth a composite view of the current understanding on the structure, functions, genetics, disease associations and therapeutic implications of CR1. (C) 2008 Elsevier Ltd. All rights reserved.

引用

页码：761 / 772

页数：12

共 132 条

[1]

ABRAHAMSON DR, 1983, LAB INVEST, V48, P162

[2]

BIPHASIC EFFECT OF OXYGEN RADICALS ON PROSTAGLANDIN PRODUCTION BY RAT MESANGIAL CELLS [J].

ADLER, S ;

STAHL, RAK ;

BAKER, PJ ;

CHEN, YP ;

PRITZL, PM ;

COUSER, WG .

AMERICAN JOURNAL OF PHYSIOLOGY, 1987, 252 (04) :F743-F749

[3]

Expression of complement regulatory proteins in diffuse proliferative glomerulonephritis [J].

Arora, M ;

Arora, R ;

Tiwari, SC ;

Das, N ;

Srivastava, LM .

LUPUS, 2000, 9 (02) :127-131

[4]

Reduced complement receptor 1 (CR1, CD35) transcription in systemic lupus erythematosus [J].

Arora, V ;

Verma, J ;

Dutta, R ;

Marwah, V ;

Kumar, A ;

Das, N .

MOLECULAR IMMUNOLOGY, 2004, 41 (04) :449-456

[5]

Modulation of CR1 transcript in systemic lupus erythematosus (SLE) by IFN-γ and immune complex [J].

Arora, Vaishali ;

Mondal, Abdul Matin ;

Grover, Rahul ;

Kumar, Ashok ;

Chattopadhyay, Parthaprasad ;

Das, Nibhriti .

MOLECULAR IMMUNOLOGY, 2007, 44 (07) :1722-1728

[6]

Therapeutic inhibition of the complement system. Y2K update [J].

Asghar, SS ;

Pasch, MC .

FRONTIERS IN BIOSCIENCE-LANDMARK, 2000, 5 :E63-E82A

[7]

Factor I-mediated processing of complement fragments on HIV immune complexes targets HIV to CR2-expressing B cells and facilitates B cell-mediated transmission of opsonized HIV to T cells [J].

Banki, Zoltan ;

Wilflingseder, Doris ;

Ammann, Christoph G. ;

Pruenster, Monika ;

Muellauer, Brigitte ;

Hollaender, Karoline ;

Meyer, Martina ;

Sprinzl, Georg M. ;

van Lunzen, Jan ;

Stellbrink, Hans-Juergen ;

Dierich, Manfred P. ;

Stoiber, Heribert .

JOURNAL OF IMMUNOLOGY, 2006, 177 (05) :3469-3476

[8]

BARBOSA JE, 1992, CLIN EXP IMMUNOL, V87, P144

[9]

Consumption of erythrocyte CR1 (CD35) is associated with protection against systemic lupus erythematosus renal flare [J].

Birmingham, DJ ;

Gavit, KF ;

McCarty, SM ;

Yu, CY ;

Rovin, BH ;

Nagaraja, HN ;

Hebert, LA .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2006, 143 (02) :274-280

[10]

A CR1 polymorphism associated with constitutive erythrocyte CR1 levels affects binding to C4b but not C3b [J].

Birmingham, DJ ;

Chen, W ;

Liang, G ;

Schmitt, HC ;

Gavit, K ;

Nagaraja, HN .

IMMUNOLOGY, 2003, 108 (04) :531-538

← 1 2 3 4 5 6 7 8 9 10 →